Management of Subtherapeutic INR in Elderly Patients on Warfarin

Immediate Assessment and Dose Adjustment

• The American College of Cardiology recommends increasing the weekly warfarin dose by 10-20% (approximately 1-2mg increase per day) for an elderly female patient with a subtherapeutic INR of 1.3, and rechecking INR within 3-5 days to ensure therapeutic range is achieved 1, 2
• Increasing the warfarin dose by 10-20% of the total weekly dose is recommended, which translates to approximately 1-2mg increase in daily dosing, to achieve a therapeutic INR range of 2.0-3.0 for most indications 2

Critical Investigation Required

• New medications that may induce warfarin metabolism, such as rifampin, carbamazepine, phenytoin, and barbiturates, should be identified as potential causes of subtherapeutic INR 1
• Dietary changes with increased vitamin K intake, such as leafy green vegetables and nutritional supplements, can also cause subtherapeutic INR 1, 3
• Medication non-adherence or missed doses is a common cause of subtherapeutic INR in elderly patients 2
• Malabsorption issues or changes in gastrointestinal function can also affect warfarin metabolism and cause subtherapeutic INR 1
• Recent illness or changes in liver function that could affect warfarin metabolism should be investigated as potential causes of subtherapeutic INR 4

Monitoring Strategy

• The American College of Cardiology recommends rechecking INR within 3-5 days after dose adjustment to assess response, as the full anticoagulant effect takes several days to manifest 1
• More frequent monitoring is essential in elderly patients due to their increased sensitivity to warfarin and higher bleeding risk at any given INR level 3

Special Considerations for Elderly Patients

• Elderly patients (≥75 years) have an increased bleeding risk even at therapeutic INR levels, particularly for intracranial and gastrointestinal bleeding 1, 3
• The American College of Cardiology notes that patients 60 years or older exhibit a greater than expected PT/INR response to warfarin, necessitating careful dose titration 1
• Lower maintenance doses are typically required in elderly patients compared to younger individuals, approximately 1mg/day less for patients ≥75 years 1

Bridging Anticoagulation Consideration

• The American College of Cardiology recommends that bridging with low molecular weight heparin (LMWH) or unfractionated heparin is NOT routinely recommended for subtherapeutic INR in stable outpatients without acute thrombotic events 1
• Bridging should only be considered if the patient has a very high thrombotic risk (mechanical heart valve, recent VTE within 3 months, acute arterial thromboembolism) and the INR is expected to remain subtherapeutic for >48 hours 1